EP.11A.26 Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data

MLA

Bitar, L., et al. “EP.11A.26 Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data.” Journal of Thoracic Oncology, vol. 19, no. 10, Number 10 Supplement 1, Oct. 2024, p. S607. EBSCOhost, https://doi.org/10.1016/j.jtho.2024.09.1137.

APA

Bitar, L., Seiwerth, F., Ljubicic, L., Bacelic-Gabelica, A., Srdic, D., Korsic, M., Plestina, S., Badovinac, S., Samarzija, M., & Jakopovic, M. (2024). EP.11A.26 Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data. Journal of Thoracic Oncology, 19(10, Number 10 Supplement 1), S607. https://doi.org/10.1016/j.jtho.2024.09.1137

Chicago

Bitar, L., F. Seiwerth, L. Ljubicic, A. Bacelic-Gabelica, D. Srdic, M. Korsic, S. Plestina, S. Badovinac, M. Samarzija, and M. Jakopovic. 2024. “EP.11A.26 Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data.” Journal of Thoracic Oncology 19 (10, Number 10 Supplement 1): S607. doi:10.1016/j.jtho.2024.09.1137.